2024
734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up)
Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Eyerich K. 734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up). British Journal Of Dermatology 2024, 191: ljae266.107. DOI: 10.1093/bjd/ljae266.107.Peer-Reviewed Original ResearchSafety of upadacitinibVenous thromboembolic eventsProportion of patientsAdverse eventsAtopic dermatitisDose escalationSystemic therapyOpen-labelSecondary endpointsAdjudicated major adverse cardiac eventsModerate-to-severe atopic dermatitisResponse to systemic therapyTreatment-emergent adverse eventsWeek 4Major adverse cardiac eventsPruritus Numerical Rating ScaleChronic inflammatory skin diseaseDiscontinuation of study treatmentEczematous skin lesionsOral Janus kinaseSevere adverse eventsAdverse cardiac eventsWeeks of treatmentNumerical rating scaleInflammatory skin diseaseBarriers to care and health-related quality of life among US adults with several common chronic inflammatory skin diseases: a cross-sectional analysis of the NIH All of Us Research Program
Nock M, Barbieri J, Cohen J. Barriers to care and health-related quality of life among US adults with several common chronic inflammatory skin diseases: a cross-sectional analysis of the NIH All of Us Research Program. Archives Of Dermatological Research 2024, 316: 201. PMID: 38775812, PMCID: PMC12085989, DOI: 10.1007/s00403-024-02954-w.Peer-Reviewed Original ResearchConceptsHealth-related quality of lifeHealth-related qualityUS adultsQuality of lifeSocial determinants of healthDeterminants of healthUs Research ProgramCross-sectional analysisNational Institutes of HealthSocial determinantsPhysician careInstitutes of HealthImpact of barriersCost barriersHRQoLAdultsNational InstituteHealthChronic inflammatory skin diseaseBarriersAoURPCarePhysiciansLifeInflammatory skin diseaseA randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis
Ehst B, Strober B, Blauvelt A, Maslin D, Macaro D, Carpenter N, Bodmer M, McHale D. A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis. Frontiers In Medicine 2024, 11: 1292406. PMID: 38813388, PMCID: PMC11133679, DOI: 10.3389/fmed.2024.1292406.Peer-Reviewed Original ResearchPASI-50Double-blindMild to moderate plaque psoriasisMild to moderate psoriasisOff-treatment responseWeeks of follow-upChronic inflammatory skin diseaseParallel-group studySystemic anti-inflammatory responsePhase 2 trialInflammatory skin diseaseAnti-inflammatory responsePlaque psoriasisPlacebo-controlledPsoriasis AreaEfficacy outcomesImmunomodulatory approachesSafety profileAdverse eventsEvaluate safetyFollow-upTreatment periodTherapeutic benefitPsoriasisSkin diseases503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice
Wang Z, Martins B, Ardeleanu M, Yang M, Bégo-Le-Bagousse G, Sierka D, Strober B. 503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice. British Journal Of Dermatology 2024, 190: ii9-ii9. DOI: 10.1093/bjd/ljad498.011.Peer-Reviewed Original ResearchHealth statusIndividual patient levelTreatment satisfactionAtopic Dermatitis Control ToolPatient levelQuality of life of childrenObservational study of adultsAtopic dermatitisLongitudinal cohort studyPatient-reported outcomesPatient support programStudy of adultsQuality of lifeDupilumab treatmentMonth 1Lives of childrenBaseline surveyChronic inflammatory skin diseasePatients maintained responseSupport programsModerate-to-severe ADCohort studyLong-term treatmentInflammatory skin diseaseOutcome trajectories
2023
Barriers to Care Among Sexual and Gender Minority Individuals With Chronic Inflammatory Skin Diseases in the US
Nock M, Kamal K, Zampella J, Roberson M, Cohen J, Barbieri J. Barriers to Care Among Sexual and Gender Minority Individuals With Chronic Inflammatory Skin Diseases in the US. JAMA Dermatology 2023, 159: 1323-1331. PMID: 37755822, PMCID: PMC10535014, DOI: 10.1001/jamadermatol.2023.3328.Peer-Reviewed Original ResearchConceptsChronic inflammatory skin diseaseInflammatory skin diseaseHealth care practitionersCross-sectional studySGM patientsPrevalence of barriersCare practitionersGender minority patientsSkin diseasesMinority patientsMAIN OUTCOMEHealth careMultivariable logistic regressionHealth care accessMental health careSpecialist careCare accessPatientsUs Research ProgramLogistic regressionCarePrevalenceDiseaseNational InstituteGender minority individualsPharmacology of orismilast, a potent and selective PDE4 inhibitor
Silverberg J, French L, Warren R, Strober B, Kjøller K, Sommer M, Andres P, Felding J, Weiss A, Tutkunkardas D, Skak‐Nielsen T, Guttman E. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. Journal Of The European Academy Of Dermatology And Venereology 2023, 37: 721-729. PMID: 36527389, DOI: 10.1111/jdv.18818.Peer-Reviewed Original ResearchConceptsChronic inflammatory skin diseasePeripheral blood mononuclear cellsEar thicknessPhosphodiesterase 4Clinical developmentBroad-spectrum anti-inflammatory activityPDE4 inhibitorsEx vivoHuman peripheral blood mononuclear cellsTumor necrosis factor αSecond-generation PDE4 inhibitorsEar skin inflammationWhole bloodMarkers of inflammationAnti-inflammatory effectsInflammatory skin diseasePro-inflammatory cytokinesBlood mononuclear cellsNovel treatment optionsNecrosis factor αPre-clinical modelsAnti-inflammatory activitySelective PDE4 inhibitorLong-term managementPBMC production
2022
Racial and ethnic differences in barriers to care among US adults with chronic inflammatory skin diseases: A cross-sectional study of the All of Us Research Program
Nock MR, Barbieri JS, Krueger LD, Cohen JM. Racial and ethnic differences in barriers to care among US adults with chronic inflammatory skin diseases: A cross-sectional study of the All of Us Research Program. Journal Of The American Academy Of Dermatology 2022, 88: 568-576. PMID: 36244557, DOI: 10.1016/j.jaad.2022.09.054.Peer-Reviewed Original ResearchConceptsChronic inflammatory skin diseaseInflammatory skin diseaseCross-sectional studyHispanic patientsUS adultsSkin diseasesUs Research ProgramEthnic differencesEthnic minority patientsHealth care workforce diversityWhite patientsAdult careMinority patientsMultivariable regressionPatientsDermatologic careCareDiseaseRepresentative sampleAdultsEthnic groupsStructural barriersEthnicityRural areasPrevalence
2019
Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index
Elnabawi YA, Oikonomou EK, Dey AK, Mancio J, Rodante JA, Aksentijevich M, Choi H, Keel A, Erb-Alvarez J, Teague HL, Joshi AA, Playford MP, Lockshin B, Choi AD, Gelfand JM, Chen MY, Bluemke DA, Shirodaria C, Antoniades C, Mehta NN. Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index. JAMA Cardiology 2019, 4: 885-891. PMID: 31365032, PMCID: PMC6669789, DOI: 10.1001/jamacardio.2019.2589.Peer-Reviewed Original ResearchConceptsPerivascular fat attenuation indexFat attenuation indexBiologic psoriasis therapyBiologic therapyCoronary inflammationSevere psoriasisPsoriasis therapyCoronary plaquesSkin diseasesAnti-tumor necrosis factor αChronic inflammatory skin diseaseDifferent biologic agentsTraditional risk scoresCoronary plaque burdenLow cardiovascular riskProspective cohort studyAnti-inflammatory effectsCoronary artery diseaseInflammatory skin diseaseCoronary atherosclerotic plaquesNecrosis factor αSevere skin diseaseCardiovascular eventsCardiovascular riskCohort study
2018
Psychological stress and psoriasis: a systematic review and meta‐analysis
Snast I, Reiter O, Atzmony L, Leshem Y, Hodak E, Mimouni D, Pavlovsky L. Psychological stress and psoriasis: a systematic review and meta‐analysis. British Journal Of Dermatology 2018, 178: e363-e363. DOI: 10.1111/bjd.16620.Peer-Reviewed Original ResearchPsychological stressStressful eventsRecalled stressful eventsLack of robust evidencePsoriasis patientsDiagnosis of stress disordersChronic inflammatory skin diseaseInfluence of psychological stressPatient recallWorsening of psoriasisInflammatory skin diseaseStress disorderPatient's memoryEvaluate disease severityRobust evidencePsoriasis onsetPsoriasis severityPsoriasisPatientsControl groupDisease severitySkin diseases
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply